Preferred Sample Type
Suitable Specimen Types
- Serum
- Li Hep
Specimen Transport
Sample sent via post to referral laboratorySample Processing in Laboratory
Sample separated and sent to referral laboratorySample Preparation
Sample collected into SST tube or Lithium Heparin tubeTurnaround Time
3 weeksSample Stability
Stable at 4C. If transport is going to be delayed by > 5 days, freeze at -20°C and send by first class post at a later date.Adalimumab drug monitoring
General Information
Measurement of Adalimumab is a useful tool in the management of patients who fail to respond ( primary failure) or lose response ( secondary failure) to treatment. Monitoring drug levels allows for a personalised approach to drug optimisation by appropriate dose escalation/de-escalation or drug switching/withdrawal. Measured as part of Adalimumab profile which includes anti drug antibodies. Specific request form required for this assay download from: http://www.viapath.co.uk/sites/default/files/upload/News/Anti-TNF%20request%20formv6.pdf
Patient Preparation
No specific preparation required.
Notes
Adalimumab is a fully humanised monoclonal antibody which specifically targets tumour necrosis factor alpha (TNFα). Adalimumab is licensed for use in Gastroenterology (Crohn's diseases, ulcerative colitis), Rheumatology (rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, juvenile idiopathic arthritis) and Dermatology (severe plaque psoriasis). Adalimumab is only indicated in patients with severe disease which is refractory to conventional therapeutic approaches
Reference Range
Lower limit of the therapeutic range is yet to be established, however levels of greater than 5 µg/mL appear to be adequate.This information will be updated as we refine the therapeutic range. Test interpretation requires full clinical information: drug dosage/frequency, previous exposure to other biologics, time of sampling, duration of therapy and clinical assessment.
Specifications
- EQA Scheme?: No
- EQA Status: No EQA scheme currently available.